2019's Programme

The Reception | 18:30 - 21:00 | Wednesday 8th May

The Wellcome Collection, 183 Euston Road, London NW1 2BE

____________________________________________________________________

The Conference | 08:15 - 18:30 | Thursday 9th May

Add agenda items to your meeting schedule: click here.

8:15 Registration opens, full continental breakfast is served

9:00 Welcome

Mattias Johansson, Director, Ezenze Ltd, Anglonordic Conference Founder

Morning session Chaired by Mary Clark, Managing Director, Optimum Strategic Communications

9:05 Keynote: Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Jefferies

9:30 Investor Panel - What’s hot and what's simmering?

Panel discussion on Investment trends, chaired by Lisa Urquart, Editor, EP Vantage

Speakers include:

Hakan Goker, Senior Investment Director, M Ventures
Stephan Christgau, Senior Partner, Novo Seeds
Henrijette Richter, Managing Partner, Sofinnova
Roel Bulthuis, Managing Director, INKEF Capital

10:30 Coffee

11:00 Company Presentations

Biotech Investment Room and Technology Room
Presentations include:

Heinz Lubenau, VAXIMM
Søren Weis Dahl, Prophylix Pharma
Andrew Woodland, In4Derm, University of Dundee
Harri Sihto, Sartar Therapeutics
Magnus Strandh, Adenium Biotech
Aidan Courtney, Censo Biotechnologies
Sally Waterman, Medherant
Clare Wareing, Cumulus Oncology
Dorte Gram, Pila Pharma
Ursula Gompels, Virokine Therapeutics
George Frodsham, MediSieve
Ole Wiborg, Zerion

____________________________________________________________________

12:30 - 13:30 Networking Lunch

____________________________________________________________________

Afternoon session Chaired by Eva Haas, Senior Consultant, Optimum Strategic Communications

13:30 Technologies and treatments - What’s on the horizon?

Panel Discussion, chaired by Lucie Ellis, Editor, In Vivo

Speakers include:

Niall Martin, CEO, Artios Pharma
Ian Wilson, CEO, ImaginAB
Sue Herbert, Head of Strategy, Merck
Dirk Beher, CEO and Founder, Asceneuron SA

14:30 Company Presentations

Biotech Investment Room and Technology Room
Presentations include:

Michael Hunt, ReNeuron
Andreas Kungl, Antagonis Biotherapeutics
Gerben Moolhuizen, ISA Pharma
Povl Verder, SIME Clinical AI
David Brooks, Ablatus
Lars-Erik Eriksson, CLS AB
Christian Jorgensen, Biotec Pharmacon
Thomas Holm Pederson, NMD Pharma A/S
Albert A. Luderer, Indi Molecular
Noor Shaker, GTN Ltd

15:45 Coffee

16:00 Challenges and opportunities for Women in European Biotech and Medtech

Panel Discussion, Chaired by Eleanor Malone, Editor, Scrip

Speakers include:

Anne Marieke Ezendam, Senior Consultant, Optimum Strategic Communications, ex-Fund Manager
Renee Aguiar-Lucander, CEO, Calliditas
Hayley French, CEO, Apitope
Ingeborg Oie, CFO, CMR Surgical

16:45 If I knew then what I know today

Panel Discussion chaired by Mike Ward, Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence

Speakers include:

Anker Lundemose, CEO, Mission Therapeutics
Edwin Moses, Chairman, Serial entrepreneur and value creator
Louise Makin, CEO, BTG
Ian Nicholson, CEO, F2G

17.45 Conclusions

17.55 - 18:45 Drinks Reception

Hosted by Mattias Johansson, Director, Ezenze Ltd

____________________________________________________________________

1:1 meetings take place throughout the day and are pre-booked online.

____________________________________________________________________

Attendees
73 Investors: 4BIO Capital, Abingworth, Advent Life Sciences, Albion Technology & General VCT, ALSA Holdings, Amadeus Capital Partners, Anvil Partners, Arix Bioscience, Arrowfield Capital, Axilium Capital, Bioscience Managers, BioSeed Capital, Bridge Valley Ventures, Catapult Ventures, Curam Capital Management, DeBere Capital Partners, Deltec International Group, FastVentures, GGS Associates, Glentworth Ventures, Hayfin Capital Management, Helsinn Investment Fund, Ignite Capital Partners, Industrifonden, INKEF Capital, Inkef Capital, Innovator Capital, Inventages Venture Capital, Investor Corporat, IP Group, IPF Partners, JJDC, Julz Co, LifeArc Seed Fund, Longacre Funding partners, LSP, M Ventures, Masselos Family Office, MEDICXI, Mercia Technologies, Molecular Warehouse, Momentum Biotech, MVM Partners, National Institute for Health Research, NCL Technology Ventures, Newable Private Investing, New Science Fund, Norgine Ventures, Novo Seeds, Novo Ventures, NVM, Optum Ventures, Panakes Partners, Rosetta Capital, Rothschild, S.R.One, SBA, Seroba Life Sciences, Seventure, Sofinnova, Start Codon, Sunstone Life Science Ventures, The Cure Parkinson's Trust, Trillium Medical Ventures, UCL Technology Fund, UKI2S, Velocity Fund Partners, Vivanova.
Delegates: Abbvie, Ablatus Therapeutics, Artios Pharma, AstraZeneca, Bayer, Eli Lilly, Johnson and Johnson Innovation, Merck, Otsuka Europe, Ablatus Therapeutics, Acesion Pharma, Adenium Biotech, Antagonis, Apitope, Arcus Altor, Arterial Capital Management, Artios Pharma, Asceneuron, Athena Market Access Solutions, AVILLION, BioCentury Publications, BioPartner UK, Biotec Pharmacon, BTG, Calliditas, Censo Biotechnologies, CLS AB, CMR Surgical, COMPASS Pathways, Cord Communications, Cumulus Oncology, Department for International Trade, DeSaque, DMNoMore, Drug Discovery Today, Embassy of Denmark, Embassy of Spain in London, Enzyre, EP Vantage, Eurofins Amatsigroup, Eurofins Selcia, Evox Therapeutics, Ezenze, F2G, Forendo Pharma, Fusion Antibodies, Global Regulatory Services, GTN Ltd, ImaginAB, Indi Molecular, International Biotechnology Trust, Invest in Denmark, ISA Therapeutics, Ixico, J A Kemp, Jefferies, Labiotech.eu, London Business School, LSX, Masters Speciality Pharma, Medherant, Medicon Valley Alliance, MediSieve, MediWales, Meeting Mojo, Mission Therapeutics, Nature Biotechnology, Neophore, NMD Pharma, Novintum Bioscience, One Nucleus, Optimum Strategic Communications, Orbit Discovery, Owkin, Oxford Cardiomox, Parkinson’s Concierge, PCI Clinical Services, Pebmond Associates, PharmaNetwork Magazine, Pharma Publications, Precision Medicine Oncology & Rare Disease, Prophylix, Public Health England, Random42, RDP Life Sciences, ReNeuron, River Stone, RTC S.p.A., RYSE Asset Management, Sartar Therapeutics, Scrip, Silicon Valley Bank, SIME Clinical AI, Spencer Stuart, Sygnature Discovery, UK BioIndustry Association (BIA), University of Dundee, VAXIMM, Verdict, Virokine Therapeutics, William Reed, Xenogesis, Zerion.